MICRO-IMMUNO
Board
3 directors, last change in 2024Director
appointed by deed of 08-01-2024
term without a fixed end
listed in the 2025 annual accounts, filed on 29-06-2026
Director
appointed by deed of 08-01-2024
term without a fixed end
listed in the 2025 annual accounts, filed on 29-06-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “Représentation et signature à l’égard des tiers Chaque administrateur représente seul la société à l’égard des tiers et dans tous les actes…”deed of 08-01-2024
Mandates through the years
4 names, the dashed line is todayManager
Director
Director
Director
BoardEarliermandate already running before its first mentionend not dated
Mandates as a list
-
- Manager, appointed by deed of 17-03-2016, still in office
-
- Director, since before 31-12-2021
-
- Director, since before 31-12-2021
-
- Director, appointed by deed of 08-01-2024, no longer listed in the 2025 annual accounts
Control
Shareholders
,
This company
MICRO-IMMUNO
Equity €916,647
Profit €31,156 in 2025
Capital
- Contribution
- €6,205.32
- Source
- 2025 annual accounts
Articles of association
deed of 08-01-2024 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Organe d'administration, seule assemblée générale nomme nouvel administrateur”
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Cession entre vifs ou pour cause de mort uniquement à Docteur en médecine légalement habilité,inscrit au Tableau,pratiquant ou appelé à…”
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- First Thursday of June at 18:00
Shareholders
Stated in the deed
deed of 08-01-2024 ↗
- actionnaire
- actionnaire
Stated in the deed
deed of 17-01-2018 ↗
- 375 shares
- 375 shares
Capital transactions
Capital over time
- 08-01-2024 Converted to unavailable equity · €9,478.54
- 08-01-2024 Converted to uncalled contributions · €12,394.68
- 17-01-2018 Capital reduction of €157,500 · to €18,600 · repaid to the shareholders